Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA First Amendment Litigation: Will Amarin Case Break The Log Jam?

Jul 02 2015

• By Brenda Sandburg

Related Content

Off-Label Prosecutions Hinge On Patient Benefit, Government Attorneys Say

Mar 11 2013

Par’s Off-Label Plea Deal Includes Clawback For Execs’ Pay In Case Of Future Misconduct

Mar 06 2013

Botox Reimbursement Training Is Driving Factor In Allergan Settlement With DOJ

Sep 01 2010

Saw Palmetto Claims Appeal Shot Down; Emord Eyes Supreme Court

Jan 19 2004

FDA Guidance On Health Care Economic Data Is Coming In 2015

Jan 02 2015

Off-Label Enforcement, Not Promotion, May See First Changes After Free Speech Ruling

Dec 10 2012

FDA Promises More Off-label Guidances As Part Of First Amendment Harmonization

Jun 11 2014

Supreme Court Reaffirms Least Restrictive Standard For Ad Controls

May 06 2002

Pearson Plaintiffs Using Shortened Omega-3 Qualified Claim

Nov 20 2000

FDA Off-Label Notice Stands, But Enforcement Still Vulnerable - Judge

Dec 11 2000

WLF Decision Could Discourage Publishing Of Studies To Avoid Piggybacking

Aug 02 1999

Rx Data Mining Opponents Will Need New Pitch After Supreme Court Strikes Down Vermont Law

Jun 23 2011

Related Companies

Amarin Corp plc

Allergan plc

Par Pharmaceutical Companies Inc.

Jazz Pharmaceuticals plc

Eli Lilly and Company

GSK plc

Novartis AG

Pfizer Inc.

Additional Topics

United States Regulation Legal Issues BioPharmaceutical

More from United States

More from North America

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window